Investor Presentaiton

Innovent: Transforming From a China Leading Biopharmaceutical Company to a Global Premier Player Fully Integrated Biopharmaceutical Platform World-class discovery, development, manufacturing and commercialization capabilities Expected 60,000L¹ production capacity by end of 2021, one of the largest in China Strong commercialization capability with a commercial team of ~2,000 people Comprehensive Global Collaboration Continued collaborations with global pharmaceutical and biotech companies Established an integrated platform with validated capabilities, striving to be the best choice for our partners XIX Innovent Note: 1) 24,000L current production capacity with additional 36,000L to be completed by 2021 Innovent 达伯舒达攸同苏立信达伯华 ® 達伯坦阿达木单抗注射液利妥昔单抗注射液 Pemazyre (tablets) Confidential Copyright©2021 Innovent Biologics Robust Pipeline in Both Oncology and Non-oncology • Robust pipeline across novel therapeutics in both oncology and non- oncology • 5 commercialized, 1 NDA under NMPA review, 5 in pivotal trials and 14 in clinical stage Global R&D Organization and Footprint Global R&D platform with 1,000+ talents in China, US and Europe • Innovent Academy as a powerful discovery engine to nourish global FIC and BIC products • First BLA of sintilimab accepted by FDA for large cancer indication, exploring global market potentials 5

View entire presentation